PSMA-Targeted Nanobodies: New Opportunities for Precision

PSMA-Targeted Nanobodies: New Opportunities for Precision Diagnosis and Treatment of Pro Cancer

Published by: ANT BIO PTE. LTD. | Official Literature Interpretation & Promotion

1. Literature Information

Document Topic: PSMA-targeted nanobodies and their applications in precision diagnosis and treatment of prostate cancer

Core Research Object: Prostate-specific membrane antigen (PSMA), single-domain nanobodies (Nb), targeted drug delivery systems

Key Detection Tool: High-specificity anti-PSMA recombinant rabbit monoclonal antibody

Application Fields: Tumor targeted imaging, precise drug delivery, personalized treatment, pathological diagnosis

2. Research Background

Prostate cancer is one of the most common malignant tumors in men worldwide. Traditional diagnostic methods represented by PSA have high false‑positive rates and cannot achieve precise localization. Conventional chemotherapy drugs such as doxorubicin have poor tumor targeting, serious systemic toxic side effects, and low clinical efficacy.

Prostate-specific membrane antigen (PSMA) is specifically highly expressed on the surface of prostate cancer cells and is a recognized ideal target for precise diagnosis and treatment. However, traditional antibody drugs have limitations such as large molecular weight, poor tissue penetration, and slow clearance, which restrict their clinical transformation.

3. Research Idea

This study focuses on PSMA as a core target and uses nanobodies as a novel targeting carrier to establish a precise “diagnosis‑treatment integration” strategy for prostate cancer. By screening high‑affinity and high‑specificity nanobodies, the research aims to realize targeted recognition, precise imaging, and controlled drug delivery for prostate cancer, so as to improve efficacy and reduce systemic toxicity.

4. Research Achievements

1. Four high‑affinity anti‑PSMA nanobodies were successfully screened, which can specifically recognize PSMA‑positive prostate cancer cells with nanomolar affinity.
2. Nanobodies have the advantages of small molecular weight, strong tissue penetration, fast blood clearance, and high tumor‑to‑normal tissue ratio.
3. The NB7‑DOX targeted conjugate can specifically kill PSMA‑positive tumor cells, significantly improving the safety and efficacy of chemotherapy.
4. Radiolabeled nanobodies can achieve precise tumor imaging, providing a new strategy for early diagnosis and recurrence monitoring of prostate cancer.
5. Molecular docking analysis clarified the multi‑site binding mechanism between nanobodies and PSMA dimers, ensuring high specificity and affinity.

5. Product Empowerment by ANTBIO

ANT BIO PTE. LTD. provides high‑performance core reagents to support the above research:

Official Core Product:

PSMA Recombinant Rabbit Monoclonal Antibody (SDT‑R075, Cat#: S0B2107)

Core Functions in Research:

1. Specifically recognize human PSMA protein, clearly locate cell membrane localization, and provide reliable IHC/IF detection tools.
2. Identify PSMA expression in clinical samples and xenograft tumor tissues, supporting pathological typing and targeted patient screening.
3. Verify the expression specificity of PSMA in tumor cells and neovascular endothelial cells, ensuring the accuracy of targeting research.
4. Provide stable and consistent detection performance, supporting long‑term and multi‑batch repeated experiments.

Core Product Advantages:

表格

Application Scenarios Supported:

• Prostate cancer pathological diagnosis and differential diagnosis
• Tumor angiogenesis labeling and evaluation
• Targeted therapy research and patient stratification
• Glioma and other PSMA‑related tumor research

6. Brand Mission

ANT BIO PTE. LTD. is a professional supplier of life science reagents, dedicated to providing high‑quality, stable, and reliable reagents for global researchers.

We have three professional sub‑brands to cover the full chain of research needs:

• Absin: Focus on general reagents, kits, and buffer solutions
• Starter: Focus on high‑quality antibodies and secondary antibodies
• UA: Focus on recombinant proteins and active proteins

We are committed to empowering scientific breakthroughs through professional products and comprehensive solutions.

7. Related Product List

1. PSMA Recombinant Rabbit Monoclonal Antibody (S0B2107)
2. IHC staining supporting kits (Absin)
3. Secondary antibodies for immunofluorescence and immunohistochemistry (Starter)
4. Recombinant human PSMA protein (UA)
5. General buffers, diluents, and blocking reagents (Absin)
6. Antibody purification and validation reagents (Starter)

Official Brand Promotion Copy

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights